TRIDENT Trial Finds No Survival Benefit From Earlier TTFields in Glioblastoma

Treatment /

The phase 3 TRIDENT trial found that starting Tumor Treating Fields (TTFields) during chemoradiation did not improve overall survival for patients with newly diagnosed glioblastoma compared with the current standard of starting treatment during the maintenance phase. The global study enrolled 981 patients. Median overall survival was 17.7 months in the early-start group and 17.5 […]

TRIDENT Trial Finds No Survival Benefit From Earlier TTFields in Glioblastoma Read More »

ST-001 Shows Early Promise for Relapsed CTCL in Phase 1 Trial

Clinical Trails /

ST-001 SST-001 nanoFenretinide showed promising early results in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, who had limited treatment options. In the Phase 1a trial, 25 heavily pretreated patients received the drug as a daily intravenous infusion for five days every three weeks. The overall response rate

ST-001 Shows Early Promise for Relapsed CTCL in Phase 1 Trial Read More »

Experimental Actinium-225 Therapy Shows Strong Results Against Ovarian Cancer in Preclinical Study

Research Advances /

A new experimental targeted alpha-particle therapy (TAT) has shown strong anti-tumor activity against ovarian cancer in preclinical research. The treatment combines an antibody that targets Folate Receptor 1 (FOLR1), a protein highly expressed in ovarian cancer, with the radioactive isotope Actinium-225, which delivers powerful alpha radiation directly to tumor cells. Researchers found that ovarian cancer

Experimental Actinium-225 Therapy Shows Strong Results Against Ovarian Cancer in Preclinical Study Read More »

Myriad Expands Personalized MRD Blood Test for Breast, Colorectal, and Renal Cancers

Treatment /

Myriad Genetics has expanded the availability of its Precise™ MRD Test for patients with breast, colorectal, and renal cancers. The personalized blood test uses whole-genome sequencing to track up to 1,000 tumor-specific genetic changes, helping detect minimal residual disease (MRD), even in cancers that release very little DNA into the bloodstream. The expansion is supported

Myriad Expands Personalized MRD Blood Test for Breast, Colorectal, and Renal Cancers Read More »

Personalized ctDNA Test Detects Osteosarcoma Relapse Months Earlier Than Imaging

Diagnostics /

A personalized circulating tumor DNA (ctDNA) test may help detect minimal residual disease (MRD) and predict relapse earlier in patients with osteosarcoma, according to a new study. Researchers created a custom blood test for each patient by sequencing their tumor and tracking its unique genetic mutations over time. Personalized ctDNA panels were successfully developed for

Personalized ctDNA Test Detects Osteosarcoma Relapse Months Earlier Than Imaging Read More »

NCCN Updates Bladder Cancer Guidelines to Include ctDNA Testing After Surgery

Treatment /

The National Comprehensive Cancer Network (NCCN) has updated its bladder cancer guidelines to recommend considering circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing after bladder removal surgery for patients with muscle-invasive bladder cancer (MIBC). This is the first time the NCCN has recognized ctDNA-MRD as both a prognostic and predictive biomarker for this disease.

NCCN Updates Bladder Cancer Guidelines to Include ctDNA Testing After Surgery Read More »

Daratumumab Retreatment Shows Promise for Older Multiple Myeloma Patients

Clinical Trails /

A phase 2 study found that retreating older patients with relapsed multiple myeloma using daratumumab, lenalidomide, and dexamethasone (DRd) remained effective even after previous daratumumab-based treatment. The GMMG-DADA trial enrolled 67 transplant-ineligible patients with a median age of 74, including many with severe kidney disease who are often excluded from clinical trials. During first-line treatment,

Daratumumab Retreatment Shows Promise for Older Multiple Myeloma Patients Read More »

FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer

Drug Approvals /

The FDA has approved Trodelvy for two first-line treatment options in adults with advanced or metastatic triple-negative breast cancer (TNBC). Trodelvy can now be used alone for patients who are not eligible for PD-1 or PD-L1 inhibitor therapy. It is also approved in combination with Keytruda for patients whose tumors have high PD-L1 expression. The

FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer Read More »

China Approves First-Ever Bispecific ADC for Advanced Nasopharyngeal Cancer

Drug Approvals /

China’s National Medical Products Administration has approved izalontamab brengitecan for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) whose disease has progressed after platinum-based chemotherapy and immunotherapy. The approval is a major milestone, making iza-bren the world’s first approved bispecific antibody-drug conjugate (ADC). The decision is based on results from the phase 3 PANKU-NPC01 Trial,

China Approves First-Ever Bispecific ADC for Advanced Nasopharyngeal Cancer Read More »

FDA Approves Ibrance-Based Maintenance Therapy for HER2-Positive Metastatic Breast Cancer

Drug Approvals /

The FDA has approved the use of Ibrance (palbociclib) together with trastuzumab, with or without pertuzumab, plus hormone therapy as a maintenance treatment for adults with hormone receptor–positive, HER2-positive advanced or metastatic breast cancer after initial treatment. The approval is based on results from the phase 3 PATINA Trial, which enrolled 518 patients. The study

FDA Approves Ibrance-Based Maintenance Therapy for HER2-Positive Metastatic Breast Cancer Read More »